Deals, Insiders

The $100M biotech club: Who’s in, and what’s it take to join the top-performing group of biopharmas?

Who doesn't love data in this business? For dealmakers and scientists alike, the proof behind any theory lies in the numbers. And we have another telling breakdown of the numbers for you today.

This third installment on dealmaking trends from DealForma's Chris Dokomajilar is based on a database involving 6,681 development deals that were struck between January 1, 2008 and today. He found more than 150 that qualified for the $100 million club, involving cash and equity payments that met the bar for a 9-figure cash deal.

These high-end deals accounted for more than $40 billion in cash, $31 billion if you’re looking at just the cash upfront minus any equity stake. It’s a key portion of the total amount that’s been invested in the industry over the past decade. And 16 of them have been written off as losers.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,700+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->